As of November 6, 2026, PMV Pharmaceuticals, Inc. is a publicly traded company (Nasdaq: PMVP); its largest reported holder is Srinivas Akkaraju, with 9.9% on Schedule 13G of September 15, 2026, then BML Investment Partners, L.P. (9.9%) (Schedule 13G, September 15, 2026).
Is this your company?
About to sign with, pay or invest in PMV Pharmaceuticals, Inc.? See the free Snapshot first.
Free to see. No signup.
Is PMV Pharmaceuticals, Inc. a real, registered company?
- PMV Pharmaceuticals, Inc. files with the SEC under CIK 1699382 (its SEC filings).
- Its shares are listed under the ticker PMVP on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Princeton, New Jersey, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under PMV Pharmaceuticals, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Leadership changes: the latest reported is Matthew Eckler, Director (Form 8-K filed 2026-10-05). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Srinivas Akkaraju (filed 2026-09-15).
Who are PMV Pharmaceuticals, Inc.'s owners and officers?
PMV Pharmaceuticals, Inc.: incorporated in Delaware; business address in Princeton, New Jersey; industry Pharmaceutical Preparations (Form D, 2026-10-05).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-09-15 | Srinivas Akkaraju | 9.9% |
| Schedule 13G/A, 2026-07-28 | Sio Capital Management, LLC | 4.94% |
| Schedule 13G/A, 2026-07-10 | Arrowmark Colorado Holdings, LLC | 3.67% |
| Schedule 13G/A, 2026-05-15 | Euclidean Capital LLC | 4.9% |
| Schedule 13G/A, 2026-05-04 | Sio Capital Management, LLC | 5.77% |
| Schedule 13D/A, 2026-03-04 | Orbimed Advisors LLC | 0% |
| Schedule 13G/A, 2026-02-17 | Arrowmark Colorado Holdings, LLC | 5.81% |
| Schedule 13G/A, 2026-02-09 | Bml Investment Partners, L.P. | 9.9% |
| Schedule 13G/A, 2025-11-12 | Sio Capital Management, LLC | 4.98% |
| Schedule 13D/A, 2025-10-27 | Orbimed Advisors LLC | 9.4% |
| Schedule 13G, 2025-09-23 | Tang Capital Management, LLC | 8.9% |
| Schedule 13G/A, 2025-08-14 | Pfm Health Sciences, LP | 0% |
Questions about who owns PMV Pharmaceuticals, Inc.
Who owns PMV Pharmaceuticals, Inc.?
On this page, 3 holders' latest ownership filings report 5% or more of PMV Pharmaceuticals, Inc.: Srinivas Akkaraju (9.9%, Schedule 13G, filed 2026-09-15), Bml Investment Partners, L.P. (9.9%, Schedule 13G/A, filed 2026-02-09) and Tang Capital Management, LLC (8.9%, Schedule 13G, filed 2025-09-23).
Who are the largest shareholders of PMV Pharmaceuticals, Inc.?
By the share each holder's latest filing reports, the largest holders of PMV Pharmaceuticals, Inc. on this page are Srinivas Akkaraju (9.9%), Bml Investment Partners, L.P. (9.9%) and Tang Capital Management, LLC (8.9%).
When did Srinivas Akkaraju buy into PMV Pharmaceuticals, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Srinivas Akkaraju on this page is the Schedule 13G, filed 2026-09-15, reporting 9.9%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on PMV Pharmaceuticals, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on PMV Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on PMV Pharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
18 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-10-05 | Matthew Eckler | Director | appointed |
Which insiders own PMV Pharmaceuticals, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- OrbiMed, a 10% owner: 4,975,291 shares (9.3% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-10-27).
- OrbiMed Capital GP V LLC, a 10% owner: 4,975,291 shares (9.3% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-10-27).
- , the chief executive and president: 508,087 shares (0.95% of shares outstanding), 451,109 held directly and 56,978 indirectly (Form 4, 2025-10-29).
- , the chief operating officer and general counsel: 98,695 shares (0.18% of shares outstanding) (Form 4, 2025-07-03).
- , the chief development officer: 89,959 shares (0.17% of shares outstanding) (Form 4, 2025-07-03).
Shares outstanding: 53,458,058 as of 2026-08-14, from the company's latest SEC cover page.
How much has PMV Pharmaceuticals, Inc. raised?
No fundraising or offering filing from PMV Pharmaceuticals, Inc. is on file with us.
Keep reading
More on PMV Pharmaceuticals, Inc. and the records around it.
PMV Pharmaceuticals, Inc. elsewhere on the record
- Leadership changes Oct 2026
- 5%+ stake filings Sep 2026
Companies that share a holder
- PFM Health Sciences, LP also filed stake reports on 2 other companies: Outset Medical, Inc. (Feb 2026), Werewolf Therapeutics, Inc. (Aug 2025)
- ArrowMark Colorado Holdings, LLC also filed stake reports on 9 other companies: Sprout Social, Inc. (Apr 2026), CIMPRESS plc (Feb 2026), ZIFF DAVIS, INC. (Feb 2026)
- Sio Capital Management, LLC also filed stake reports on 9 other companies: Enveric Biosciences, Inc. (Nov 2026), Adagio Medical Holdings, Inc. (Jul 2026), Anteris Technologies Global Corp. (May 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/pmv-pharmaceuticals